SecurAcath Significantly Reduces Catheter-Related Infection Risk

PLYMOUTH, Minn.--(BUSINESS WIRE)-- Interrad Medical, a privately held medical device company, announces a new clinical data publication that shows a significantly lower catheter-related infection risk with use of the SecurAcath Subcutaneous Catheter Securement Device.

The article titled: Catheter Securement Impact on PICC-related CLABSI: A University Hospital Perspective, Rowe, et al, was published in American Journal of Infection Control, Open Access, June 17, 2020.

This retrospective, observational quality review performed at the University of Arkansas for Medical Sciences (UAMS) analyzed 7,779 patients over four years of Central Line Associated Bloodstream Infection (CLABSI) data. This study sought to understand the impact of securement devices on the CLABSI rate in patients who had PICCs. Analysis compared outcomes of patients whose PICCs were secured with a the SecurAcath to those secured with an adhesive device.

The study found a substantial difference in relative risk among securement devices utilized in their population. The analysis showed those who had an adhesive device had a 288% increase in risk of CLABSI compared to those who had a SecurAcath. The difference in practice demonstrated direct positive impact on patient outcomes when using SecurAcath verses an adhesive securement device.

The occurrence of CLABSIs yield tremendous negative consequences affecting patients and health care facilities associated with morbidity, mortality, and financial burdens. The CDC estimates the annual cost of CLABSI is more than $1 billion, the cost per patient is more than $16,000.

Mark Rowe, MNSc, RNP, VA-BC, Sr. Vascular Access Specialist, UAMS, stated, “We have been very pleased with the improved catheter securement and reduced complications with the SecurAcath including lower CRBSI risk, catheter dislodgements, and line replacements.”

“This important and exciting new infection reduction data supports the fact that the SecurAcath improves outcomes, increases efficiencies, and lowers the cost of patient care,” commented Joe Goldberger, President and CEO of Interrad Medical.

The SecurAcath is the only subcutaneous catheter securement device that lasts the life of the line and can reduce catheter-related infections and other complications, dramatically decrease catheter dislodgement and migration, decrease catheter replacement costs, and lower total cost of patient care.

About Interrad Medical, Inc.

Plymouth, Minnesota-based Interrad Medical, Inc. is a developer, manufacturer and marketer of medical devices designed for minimally-invasive interventional and surgical procedures. Learn more at www.securacath.com

This press release contains forward-looking statements. The Company wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with litigation, clinical trials, the regulatory approval process, reimbursement policies and commercialization of new technologies.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200624005535/en/

Jeff Killion, Chief Marketing Officer
763-225-6699

Source: Interrad Medical

You May Also Be Interested In

• Google unveils Gemini 4 Carbon with advanced cybersecurity features
• Align Technology names former P&G healthcare CEO as next leader
• Adial Pharmaceuticals rebrands as Azora Therapeutics, ticker AZR